Berlin (Reuters) – Health Minister Karl Lauterbach wants to present his plans for a medical research law at the pharmaceutical industry meeting in the Chancellery on Thursday.
“The law is intended to simplify, speed up and reduce bureaucracy in clinical studies,” the SPD politician told the “Frankfurter Allgemeine Zeitung” according to the preliminary report. In a few years, we want to be at the same level as the USA as a research and production location. However, no decisions were made at the meeting with industry representatives, said a government spokesman. The shortage of medicines in some areas will also be an issue. In addition to Chancellor Olaf Scholz (SPD), Economics Minister Robert Habeck (Greens) also takes part in the meeting.
In order to reduce dependencies, the federal government and the EU Commission want to locate more pharmaceutical production in Germany and Europe. The US group Eli Lilly recently announced that it would invest around 2.3 billion euros in a new plant in Alzey, Rhineland-Palatinate.
(Report by Andreas Rinke; edited by Scot W. Stevenson; If you have any questions, please contact our editorial team at [email protected] (for politics and economics) or [email protected] (for companies and markets) .)
Selected leverage products on BASF
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on BASF
The leverage must be between 2 and 20
Advertising